source
- Johnson & Johnson’s depression drug JNJ-5120 fails primary endpoint in phase 2 trialA phase 2 study of JNJ-5120, an M1 receptor antagonist developed by Johnson & Johnson with Contineum Therapeutics, did not meet its primary efficacy endpoint in patients with major depressive disor…
- Summit and Akeso report ivonescimab extends lung cancer survival by eight months versus Keytruda in Phase 3 trialSummit Therapeutics and its partner Akeso said their experimental dual-target drug ivonescimab added about eight months of overall survival for patients with lung cancer compared with Merck's Keytr…